Form 4: Centessa Pharmaceuticals Acquisition Complete

Centessa Pharmaceuticals plc's acquisition by Eli Lilly and Company is finalized, with shareholders receiving cash and contingent value rights.

Summary

• This filing reports changes in beneficial ownership for John J. Crowley, Chief Financial Officer of Centessa Pharmaceuticals plc.
• The report details transactions occurring on June 24, 2026, related to the acquisition of Centessa Pharmaceuticals plc by Eli Lilly and Company.
• As part of the acquisition, ordinary shares and share options held by Mr. Crowley were converted into rights to receive cash and contingent value rights (CVRs).
• Specifically, ordinary shares were converted into $38.00 in cash per share plus one CVR per share.
• Restricted Share Units (RSUs) were also converted into $38.00 in cash per share underlying the RSU, plus one CVR per underlying share.
• Share options were converted into cash equal to the excess of the $38.00 cash consideration over the option's exercise price, plus one CVR per underlying share.
• The acquisition was completed via a scheme of arrangement under UK law, with Eli Lilly's subsidiary LDH XV Corporation acting as the purchaser.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, as the acquisition by a major pharmaceutical company and the cash payout provide a clear and favorable outcome for existing shareholders and option holders, despite the contingent nature of additional payments.

Positives

• Shareholders, including management, are set to receive a significant cash payout of $38.00 per ordinary share.
• The inclusion of a contingent value right (CVR) offers potential for additional future payments up to $9.00 per ordinary share, contingent on achieving specified milestones.
• The acquisition by a major pharmaceutical company like Eli Lilly and Company suggests a positive valuation of Centessa's assets and pipeline.

Negatives

• The filing indicates the cancellation of all outstanding share options and RSUs, converting them into cash and CVRs, which may not be favorable for option holders if the exercise price was significantly below the cash consideration.
• The contingent nature of the CVR payments introduces uncertainty regarding the ultimate value received by former shareholders and option holders.

Risks

• The realization of the contingent payments associated with the CVRs is dependent on the achievement of specified milestones, which are not guaranteed.
• Potential for disputes or disagreements regarding the achievement of milestones and the calculation of contingent payments.

Future Outlook

The future outlook for former Centessa shareholders and option holders is tied to the achievement of specific milestones outlined in the Contingent Value Rights Agreement, which could result in additional payments of up to $9.00 per ordinary share.

Management Comments

• The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Person.
• At the Effective Time, each outstanding and unvested RSU became fully vested, and at the Effective Time, each RSU was automatically cancelled and converted into the right to receive cash and a CVR.
• At the Effective Time, each outstanding share option, whether or not vested, was automatically cancelled and converted into the right to receive cash and a CVR.

Industry Context

StockSavvy.ai notes that this Form 4 filing confirms the completion of a significant acquisition in the pharmaceutical sector, a common occurrence driven by pipeline advancements and strategic consolidation. The structure involving cash and contingent value rights is a typical mechanism used in such deals to bridge valuation gaps and incentivize future performance.

Comparison to Industry Standards

• The cash consideration of $38.00 per share represents a premium over the typical trading price prior to the announcement of the acquisition, aligning with industry standards for successful M&A transactions.
• The inclusion of a CVR, offering up to $9.00 per share, is a common feature in biopharmaceutical acquisitions, particularly when the target company has assets in development. This structure is seen in deals involving companies like Kadmon Pharmaceuticals (acquired by Sanofi) and Alexion Pharmaceuticals (acquired by AstraZeneca), where contingent payments were tied to regulatory approvals or sales targets.

Stakeholder Impact

• Shareholders: Receive $38.00 cash per share plus potential future payments via CVRs.
• Option Holders: Receive cash based on the spread between exercise price and $38.00, plus CVRs.
• Employees: RSUs and options converted into cash and CVRs, potentially impacting compensation realization.
• Creditors: The acquisition by Eli Lilly and Company, a financially strong entity, likely provides stability and assurance for existing creditors.

Next Steps

• Former Centessa shareholders and option holders will receive the cash consideration and CVRs as per the terms of the acquisition.
• The realization of CVR payments will depend on the achievement of specified milestones by the acquired entity under Eli Lilly's ownership.

Key Dates

Recommendation

For existing shareholders and option holders, the primary action is to receive the transaction proceeds. For external investors, the focus shifts to Eli Lilly and Company (CNTA's acquirer), and this filing itself does not provide new investment information on CNTA as an independent entity. Therefore, a 'hold' recommendation is appropriate for those who may still hold shares or related instruments, pending the realization of CVRs.

Keywords

Centessa Pharmaceuticals, Eli Lilly and Company, Acquisition, Form 4, Beneficial Ownership, Shareholder Rights, Contingent Value Rights, Scheme of Arrangement, John J. Crowley, CNTA